Connection

Richard Silver to Hypertension, Pulmonary

This is a "connection" page, showing publications Richard Silver has written about Hypertension, Pulmonary.
Connection Strength

1.727
  1. Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis. J Comput Assist Tomogr. 2014 Mar-Apr; 38(2):163-8.
    View in: PubMed
    Score: 0.374
  2. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000 Oct; 118(4):1077-82.
    View in: PubMed
    Score: 0.148
  3. Assessment and management of scleroderma lung disease. Curr Opin Rheumatol. 1999 Nov; 11(6):508-13.
    View in: PubMed
    Score: 0.139
  4. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
    View in: PubMed
    Score: 0.129
  5. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2017 May; 14(5):682-689.
    View in: PubMed
    Score: 0.117
  6. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
    View in: PubMed
    Score: 0.113
  7. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug; 76(8):1327-1339.
    View in: PubMed
    Score: 0.113
  8. Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am. 1996 Nov; 22(4):825-40.
    View in: PubMed
    Score: 0.113
  9. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95.
    View in: PubMed
    Score: 0.094
  10. Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-21-7.
    View in: PubMed
    Score: 0.092
  11. Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension. Am J Pathol. 2013 Jun; 182(6):2391-406.
    View in: PubMed
    Score: 0.088
  12. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol. 2009 Feb; 36(2):330-6.
    View in: PubMed
    Score: 0.066
  13. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007 Jun; 34(6):1277-82.
    View in: PubMed
    Score: 0.058
  14. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum. 2015 Jun; 44(6):680-6.
    View in: PubMed
    Score: 0.025
  15. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov; 72(11):1747-55.
    View in: PubMed
    Score: 0.023
  16. Lung disease in systemic sclerosis (scleroderma). Baillieres Clin Rheumatol. 1993 Feb; 7(1):79-97.
    View in: PubMed
    Score: 0.022
  17. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009 May; 68(5):620-8.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.